Clinical Trial Update: BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study of BIIB023 in lupus nephritis was terminated, with results posted in January 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• BIIB023

Snippet

Sponsor: Biogen | Conditions: Lupus Nephritis | Phase 2 | Status: TERMINATED | Results posted: 2017-01-18